Építés alatt – nem éles oldal
Belépés
Résztvevőt keres itt: Egyesült ÁllamokFázis nélkül

A Study to Learn How Nusinersen (Spinraza) Affects Participants With Spinal Muscular Atrophy (SMA) Who Took it Before or During Pregnancy And About The Health of Their Babies

A legfontosabb adatok

Ki végzi
Biogen
Hol
Boston, Cambridge, New York és Palo Alto (Egyesült Államok)Mind a 4 helyszín megnézéseMég 1 másik országban, 10 helyszínen
Azonosító
Állapot
Toboroz
Résztvevők
20 fő, tervezett
Kezdés
2023. dec. 15.
Várható befejezés
2033. okt. 31.
A vizsgálat típusa
Megfigyeléses
A regiszteradat frissítve
2026. november 12.

Ki vehet részt

Életkor
18 év – 54 év
Nem
Csak nők
Egészséges önkéntesek
Nem vehetnek részt

A regiszter feltételei, szó szerint

Mind a 5 feltétel megnézéseKevesebb

Ki vehet részt

  • Participant who is currently pregnant (or was pregnant during the relevant exposure window) and enrolled in the United States (US) network of the ISMAR registry, the United Kingdom (UK) Adult SMA REACH, the Germany, Austria, Switzerland network of the SMArtCARE registry, or the Polish SMA Patient registry
  • Genetic documentation of spinal muscular atrophy linked to chromosome 5q (5q SMA)
  • Documentation that the participant was exposed to nusinersen 12 or 50/28 mg up to 14 months prior to the first day of their last menstrual period (LMP) before conception, 14.5 months before conception, and/or at any time during their pregnancy

Ki nem vehet részt

  • Treatment with risdiplam at any time from the first day of their LMP, 2 weeks prior to the date of conception (approximately 5 half-lives), and/or plans to receive treatment with risdiplam during pregnancy
  • Ever treated with intrathecal or intravenous onasemnogene abeparvovec; NOTE: Other protocol defined Inclusion/Exclusion criteria may apply

Nézd meg, megfelelhetsz-e

Magadról válaszolj. Ez nem döntés: hogy részt vehetsz-e, azt csak a vizsgálat csapata mondhatja meg.

  • 18 és 54 év között vagy?

Helyszínek itt: Egyesült Államok

Még 1 másik országban, 10 helyszínen

  • Boston Children's HospitalBoston, Egyesült ÁllamokContact: Basil T. Darras (principal investigator)Résztvevőt keres
  • Cambridge, MassachusettsHospital not named in the registryContact: US Biogen Clinical Trial CenterNo longer taking part
  • Columbia University Irving Medical CenterNew York, Egyesült ÁllamokContact: Michio Hirano (principal investigator)Résztvevőt keres
  • Stanford Neuroscience Health CenterPalo Alto, Egyesült ÁllamokContact: John W. Day (principal investigator)Résztvevőt keres

A vizsgálatról

Mit akar kideríteni a vizsgálat

In this study, researchers will know more about the effects of nusinersen, also known as Spinraza®, in pregnant participants with spinal muscular atrophy, also known as SMA. This is a drug available for doctors to prescribe for people with SMA. Due to the current treatment options that exist, people with SMA may now reach the age where they can become pregnant. But, there is not enough information known yet about what the effects of nusinersen may be on pregnant people with SMA or on their babies.

A teljes eredeti leírásKevesebb

This is known as an "observational" study, which collects health information about study participants without changing their medical care. The pregnant participants for this study will be found using 3 different groups of SMA study research centers:

* ISMAR-US (International SMA Registry in the United States) * UK Adult SMA-REACH (Adult SMA Research and Clinical Hub in the United Kingdom) * SMArtCARE (Austria, Germany, and Switzerland) * Polish SMA Patient Registry

The main goal of this study is to collect birth and health information from 3 groups of participants and their babies. These groups are:

* Those who received nusinersen up to 14 months before the first day of their last period before getting pregnant. This was either the standard dose of 12 milligrams (mg) of nusinersen or the higher dose (50/28 mg). * Those who received nusinersen 14.5 months before the day they got pregnant * Those who received 12 mg or 50/28 mg of nusinersen during any time in their pregnancy

The main questions researchers want to learn about in this study are:

* Loss of pregnancy overall * Loss of pregnancy before the baby was 20 weeks old * Loss of pregnancy after the baby becomes 20 weeks old * Live births * Loss of the baby after birth * Babies who have problems in their body that develop during pregnancy * Babies who are small for their age while in the participant's uterus * Pregnancy that happens outside of the uterus * How many participants die during pregnancy, while the baby is being born, and up to 12 weeks after delivering the baby * Babies who develop problems in their body after birth

Researchers will also compare this information to people without SMA who have not received nusinersen.

This study will be done as follows:

* Information will start being collected when the participant decides to join the study. * Participants will be contacted at each trimester (about every 3 months) to learn about their health and pregnancy. * Participants' doctors will be contacted at each trimester, when the participants are about 6 or 7 months pregnant, and about 4 weeks after the delivery of the baby. * The babies' doctors will be contacted when the baby is 1, 2, 6, 12, 18, and 24 months old. * Each participant will be in the study until the end of their pregnancy and for up to 12 weeks after delivery. Each baby will be in the study for up to 2 years after birth. * The study overall will last at least 10 years from when the first participant joins the study.

A vizsgálat csoportja

  • Nusinersen Treated Participants

    Pregnant participants with SMA who are exposed to 12 or 50/28 mg nusinersen during the relevant window defined as 14 months prior to the first day of the participant's last menstrual period before conception, 14.5 months before conception and anytime during pregnancy and are enrolled in the registries, International Spinal Muscular Atrophy Registry (ISMAR), Adult SMA REACH, SMArtCARE and Polish SMA Patient registry will be followed prospectively up to 3 months post-delivery, the infants will be followed up to 2 years post-delivery and the available data is collected retrospectively.

Kérdések a vizsgálat csapatának

  1. Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
  2. Megtérítik az utazási költséget?
  3. Megtarthatom a saját orvosomat?
  4. Mi történik, ha ki akarok lépni?

Contact the study team: see the registry record → Contacts and Locations

Oldal nyomtatása az orvosomnak

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
Spinraza (Nusinersen) SMA Pregnancy Exposure Study Within Existing SMA Registries
Illeszkedési kérdések
Forrás: NCT05789758: ki vehet részt
A regiszteradat frissítve
2026. november 12.